Il y a eu 25 transactions d'initiés récentes enregistrées pour NeuroSense Therapeutics Ltd. (NRSN), dont 3 achats et 0 ventes.
Les initiés notables ayant une activité récente comprennent Binder Hagit, Russek-blum Niva, Eisenberg Or. Les transactions d'initiés peuvent fournir des indications sur la façon dont la direction perçoit la valorisation et les perspectives futures de l'action.
Transactions d'Initiés — NRSN
| Date |
Nom |
Rôle |
Type de Transaction |
Actions |
Prix Moyen |
Valeur |
Actions détenues |
| 2026-03-26 |
Binder Hagit |
General Manager |
Attribution de RSU |
200,000 |
- |
- |
521,806 |
| 2026-03-26 |
Russek-blum Niva |
Chief Technology Officer |
Attribution de RSU |
200,000 |
- |
- |
467,953 |
| 2026-03-26 |
Eisenberg Or |
Chief Financial Officer |
Attribution de RSU |
200,000 |
- |
- |
1,254,050 |
| 2026-03-18 |
Pellizzari Christine A |
Director |
Inconnu |
- |
- |
- |
48,000 |
| 2026-03-18 |
Leuchtenberger Mark |
Director |
Inconnu |
- |
- |
- |
75,000 |
| 2026-03-18 |
Claiborne Cary J |
Director |
Inconnu |
- |
- |
- |
48,000 |
| 2026-03-18 |
Golan Roy |
Director |
Inconnu |
- |
- |
- |
24,000 |
| 2026-03-18 |
Binder Hagit |
General Manager |
Inconnu |
- |
- |
- |
10,000 |
| 2026-03-18 |
Tracik Ferenc |
Chief Medical Officer |
Inconnu |
- |
- |
- |
189,618 |
| 2026-03-18 |
Ben-noon Alon |
10 Percent Owner, Officer: Chief Executive Officer |
Inconnu |
- |
- |
- |
360,777 |
| 2026-03-18 |
Russek-blum Niva |
Chief Technology Officer |
Inconnu |
- |
- |
- |
10,000 |
| 2026-03-18 |
Mandil-levin Revital |
Director |
Inconnu |
- |
- |
- |
52,526 |
| 2026-03-18 |
Eisenberg Or |
Chief Financial Officer |
Inconnu |
- |
- |
- |
139,416 |
| 2024-12-05 |
Ben-noon Alon |
10 Percent Owner, Officer: Chief Executive Officer |
Inconnu |
80,000 |
$1.25 |
$100K |
- |
| 2024-08-15 |
Tracik Ferenc |
Chief Medical Officer |
Inconnu |
66,667 |
$0.75 |
$50K |
- |
| 2024-08-15 |
Ben-noon Alon |
10 Percent Owner, Officer: Chief Executive Officer |
Inconnu |
26,666 |
$0.75 |
$20K |
- |
| 2024-08-15 |
Eisenberg Or |
Chief Financial Officer |
Inconnu |
66,666 |
$0.75 |
$50K |
- |
| 2023-03-10 |
Pellizzari Christine A |
Director |
Inconnu |
72,000 |
$1.43 |
$102.96K |
- |
| 2023-03-10 |
Claiborne Cary J |
Director |
Inconnu |
72,000 |
$1.43 |
$102.96K |
- |
| 2023-03-10 |
Mandil-levin Revital |
Director |
Inconnu |
72,000 |
$1.43 |
$102.96K |
- |
| 2022-11-17 |
Binder Hagit |
General Manager |
Inconnu |
36,000 |
$1.99 |
$71.64K |
- |
| 2022-04-25 |
Russek-blum Niva |
Chief Technology Officer |
Inconnu |
36,000 |
$2.18 |
$78.48K |
- |
| 2022-03-13 |
Tracik Ferenc |
Chief Medical Officer |
Inconnu |
108,000 |
$3.51 |
$379.08K |
- |
| 2022-01-01 |
Leuchtenberger Mark |
Director |
Inconnu |
192,000 |
$3.51 |
$673.92K |
- |
| 2021-07-01 |
Eisenberg Or |
Chief Financial Officer |
Inconnu |
21,000 |
$0.03 |
$693.00 |
- |
■ Informatif — transaction sur marché ouvert (la plus significative)
■ Non informatif (achat) — récompense, exercice d'option, conversion
■ Non informatif (vente) — retenue fiscale, vente à l'acquisition
■ Neutre — don, fiducie, expiration
Les autres consultent aussi
